### Project Information

**HAMLET-BC**  
Grant agreement ID: 954360

**Funded under**  
INDUSTRIAL LEADERSHIP - Innovation In SMEs

**Total cost**  
€ 3 138 778,00

**EU contribution**  
€ 2 197 144,59

**Coordinated by**  
HAMLET PHARMA AB  
Sweden

**Start date**  
1 June 2020  
**End date**  
30 November 2022

### Project description

**Novel highly efficient bladder cancer treatment with low toxicity**

The ideal cancer treatment should combine great efficacy with high selectivity. The Swedish HAMLET Pharma AB develops revolutionary cancer treatments on a peptide-based platform for targeting and killing tumor cells with high precision. Their proprietary drug complex is derived from the human breast milk protein, alpha-lactalbumin, and represents a therapeutic solution with high tumor-killing capacity, high target specificity, no demonstrated toxicity, killing more than 40 different types of tumor cells. The EU-funded HAMLET-BC project will advance this drug complex in combination with the synthetic drug candidate Alpha1H into the clinical development...
pipeline as an early-stage treatment for bladder cancer, which has the highest recurrence rate among all cancer types.

**Fields of science**

medical and health sciences ➔ basic medicine ➔ pharmacology and pharmacy ➔ drug discovery
medical and health sciences ➔ clinical medicine ➔ oncology ➔ bladder cancer
natural sciences ➔ biological sciences ➔ biochemistry ➔ biomolecules ➔ proteins

**Keywords**

- Bladder cancer
- non-muscle invasive bladder cancer
- tumour
- oncology
- anti-cancer
- therapeutic
- drug development
- lactalbumin
- human breast milk
- protein-lipid complex
- biological
- prophylactic

**Programme(s)**

- H2020-EU.2.3. - INDUSTRIAL LEADERSHIP - Innovation In SMEs
- H2020-EU.3. - PRIORITY 'Societal challenges
- H2020-EU.2.1. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies

**Topic(s)**

- EIC-SMEInst-2018-2020 - SME instrument

**Call for proposal**

- H2020-EIC-SMEInst-2018-2020

**See other projects for this call**

**Sub call**

Funding Scheme

SME-2 - SME instrument phase 2

Coordinator

HAMLET PHARMA AB
Net EU contribution
€ 1 995 165,43

Address
Klinikgatan 32
222 42 Lund
Sweden

Region
Södra Sverige > Sydsverige > Skåne län

Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)

Links
Contact the organisation
Participation in EU R&I programmes
HORIZON collaboration network

Other funding
€ 855 070,91

Participants (1)

THIRD-PARTY

LINNANE PHARMA AB
Sweden
Net EU contribution
€ 201 979,16

Address
Slottsgatan 32
211 33 Malmö

SME
Yes
Region
Södra Sverige > Sydsverige > Skåne län

Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)

Links
Contact the organisation
Participation in EU R&I programmes
HORIZON collaboration network

Other funding
€ 86 562,50

EC signature date 11 June 2020
Last update: 13 June 2023

Permalink: https://cordis.europa.eu/project/id/954360

European Union, 2023